Colchicine, COVID-19 and hematological parameters: A meta-analysis.

Musharraf SarwarZahid AliMahnoor FatimaZouina Sarfraz Piero SchiròIvan Cherrez-Ojeda

Published in: Journal of clinical laboratory analysis (2021)

Colchicine has efficacy in reducing inflammatory biomarkers observed in moderate-to-severe COVID-19 patients. It may be worthwhile to consider monitoring the clinical and laboratory parameters of patients in further trials to consider colchicine as a strong candidate for an adjunct to COVID-19 treatment.

Keyphrases

sars cov
coronavirus disease
end stage renal disease
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
respiratory syndrome coronavirus
high intensity